Ray Dalio
ONC

Ray Dalio’s BeOne Medicines Ltd ONC Stock Holding History

Ray Dalio’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-772
Closed -$210K – 747
2025
Q1 		$210K Sell
772
-838
-52% -$196K ﹤0.01% 646
2024
Q4 		$297K Buy
+1,610
New +$329K ﹤0.01% 630
2023
Q3 		– Sell
-12,118
Closed -$2.16M – 819
2023
Q2 		$2.16M Sell
12,118
-119,999
-91% -$27.6M 0.01% 449
2023
Q1 		$28.5M Sell
132,117
-56,248
-30% -$13.5M 0.17% 106
2022
Q4 		$41.4M Sell
188,365
-148,132
-44% -$27.2M 0.23% 89
2022
Q3 		$45.4M Buy
336,497
+5,355
+2% +$920K 0.23% 90
2022
Q2 		$53.6M Sell
331,142
-52,676
-14% -$8.23M 0.23% 93
2022
Q1 		$72.4M Buy
383,818
+154,335
+67% +$32.8M 0.29% 63
2021
Q4 		$62.2M Buy
229,483
+53,560
+30% +$18.1M 0.36% 49
2021
Q3 		$63.9M Buy
175,923
+89,877
+104% +$29.4M 0.35% 55
2021
Q2 		$29.5M Buy
86,046
+12,993
+18% +$4.3M 0.19% 93
2021
Q1 		$25.4M Buy
73,053
+52,254
+251% +$17.3M 0.22% 93
2020
Q4 		$5.37M Buy
+20,799
New +$5.73M 0.05% 189

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ray Dalio's ONC Position: Q2 2025 in Review

Ray Dalio sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 772 shares — an estimated $210K sold.

Ray Dalio first reported a position in ONC in Q4 2020 and held it in 13 quarters. The position peaked at $72.4M in Q1 2022. 244 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

  • Ray Dalio reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
  • Ray Dalio sold 772 BeOne Medicines Ltd shares in Q2 2025, an estimated $210K.
  • Ray Dalio first reported a position in BeOne Medicines Ltd in Q4 2020 and held it in 13 quarters.
  • Ray Dalio's BeOne Medicines Ltd position peaked at $72.4M in Q1 2022.
  • 244 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Bridgewater Associates's 13F filing for Q2 2025, filed 13 Aug 2025.